Fosun Pharma is planning to spin off and conduct a Hong Kong IPO of a subsidiary, IVD maker Yaneng Bioscience of Shenzhen; KHB Shanghai Kehua Bio-Engineering paid $31.5 million to acquire Technologenetics of Italy, a fellow IVD developer, which it will combine with a third IVD company, Altergon Italia; Samsung BioLogics of South Korea began construction of a $730 million biologics drug production facility in Korea, giving the company a total annual capacity of 360,000 liters; SciClone Pharma will develop a treatment for oral mucositis that it acquired from Soligenix of the US; and BeyondSpring Pharma, a New York virtual immuno-oncology cancer company, received approval to conduct a China arm of its lead drug, plinabulin, as part of a global Phase III trial in patients with lung cancer.
